{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-298441","form_type":"8-K","ticker":"JAZZ","cik":"0001232524","company_name":"Jazz Pharmaceuticals plc","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.889904+00:00","generated_at":"2026-06-21T09:26:04.039240+00:00","sec_items":["2.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Jazz acquires exclusive zanidatamab rights from Zymeworks for $50M upfront","bullets":["Upfront $50M non-refundable cash payment; potential $325M payment after HERIZON-BTC-01 top-line data.","Regulatory milestones up to $525M; commercial milestones up to $862.5M.","Tiered royalties of 10%-20% on annual net sales in the Territory.","Exclusive rights in U.S., Europe, Japan; Asia/Pacific territories excluded per prior BeiGene license.","Agreement effective Nov 29, 2022 following HSR clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-298441","json":"https://secwatch.observer/filing/0001193125-22-298441.json","markdown":"https://secwatch.observer/filing/0001193125-22-298441.md","text":"https://secwatch.observer/filing/0001193125-22-298441.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1232524/000119312522298441/0001193125-22-298441-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1232524/000119312522298441/d428448d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:26:04.039240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}